Core Insights - Mounjaro (tirzepatide) demonstrated non-inferiority to Trulicity (dulaglutide) in reducing major adverse cardiovascular events (MACE-3) with an 8% lower rate of such events [1][2] - Mounjaro showed a 16% reduction in all-cause mortality compared to Trulicity, indicating broader health benefits [1][2] - The SURPASS-CVOT trial is the largest and longest study of tirzepatide, involving over 13,000 participants across 30 countries [1][6] Group 1: Trial Results - Mounjaro achieved a hazard ratio of 0.92 for MACE-3 events, meeting the criteria for non-inferiority [2][3] - The trial reported a 39% reduction in all-cause mortality when comparing Mounjaro to a hypothetical placebo [2][3] - Mounjaro also showed a significant improvement in estimated glomerular filtration rate (eGFR) decline in patients with chronic kidney disease, with a treatment difference of 3.54 mL/min/1.73 m² at 36 months [2][3] Group 2: Efficacy and Safety - Mounjaro led to greater reductions in A1C levels and body weight compared to Trulicity, with a treatment difference of -0.83% in A1C and -7.1% in body weight [4][5] - The most common adverse events for both Mounjaro and Trulicity were gastrointestinal-related, with 13.3% of Mounjaro participants discontinuing treatment due to adverse events compared to 10.2% for Trulicity [5][6] - Safety profiles for both drugs were consistent with established data, indicating that Mounjaro is a viable option for patients with type 2 diabetes and cardiovascular disease [2][5]